Eli Lilly & Co. raised its full-year sales forecast as demand for its blockbuster obesity and diabetes drugs continues to surge, giving the drugmaker more momentum as it expands into pills and develops even more powerful weight-loss treatments.
Please sign in to ensure you can read our agenda-setting intelligence, analysis and advice.
Or get in touch at support@businessoffashion.com
if you experience difficulties.
